Search
tositumomab (Bexxar)
Tradename: Bexxar (FDA approved 2003)
Indications:
- refractory non-Hodgkin's lymphoma
Mechanism of action:
-> radiolabeled monoclonal antibody against CD20
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
Prescriber's Letter 11(2):suppl 2004
Component-of
iodine/tositumomab